Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wakunaga Pharmaceutical Co. Ltd.

Latest From Wakunaga Pharmaceutical Co. Ltd.

Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity

Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.

BioPharmaceutical United States

Dainippon Sumitomo wins long-running licensing dispute with Wakunaga

Dainippon Sumitomo Pharma (DSP) has prevailed in a legal case brought against it by a smaller Japanese company regarding a terminated licensing deal for a quinolone antibacterial.


Wakunaga takes Japanese quinolone case to Supreme Court

Wakunaga Pharmaceutical has taken its fight with fellow Japanese company Dainippon Sumitomo Pharma (DSP) to the Supreme Court. The small firm has appealed a recent Osaka High Court decision that rejected its claims against DSP in a long-running dispute over a terminated 1998 licensing deal for a quinolone antibacterial. DSP brought the High Court appeal following a 2007 district court decision ordering it to pay ¥890 million ($8.9 million) in damages to Wakunaga (, March 27th, 2009). Wakunaga first filed suit in 2004, claiming then that Dainippon (which merged with Sumitomo Pharma in 2005) had acted improperly.


Japan high court favours DSP in quinolone case

Dainippon Sumitomo Pharma (DSP) has won the latest round in a legal battle with fellow Japanese company Wakunaga Pharmaceutical over a terminated 1998 licensing deal for a quinolone antibacterial.

See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Wakunaga Pharmaceutical Co. Ltd.
  • Senior Management
  • Gisuke Wakunaga, Pres., CEO
    Yoshi Hirokusai, VP, Licensing
    Tohru Fuwa, PhD, R&D
  • Contact Info
  • Wakunaga Pharmaceutical Co. Ltd.
    Phone: (81) 663503555
    4-5-36 Miyahara, Yodogawa-ku
    Osaka City, Osaka, 541 -